Introduction
============

The prevalence of COPD is increasing globally, and COPD has become a major cause of mortality.[@b1-copd-13-867],[@b2-copd-13-867] In patients with COPD, respiratory tract infections such as pneumonia are a common cause of COPD exacerbations, and frequent exacerbations can result in a greater decline in health status. In addition, patients with COPD are at a higher risk of pulmonary infection than the general population.[@b3-copd-13-867],[@b4-copd-13-867] Moreover, many studies[@b5-copd-13-867]--[@b7-copd-13-867] have shown that inhaled and systemic corticosteroid therapy, which is frequently used to control COPD and manage COPD exacerbations, can further increase the risk of pneumonia. Therefore, preventing pneumonia in patients with COPD has become an important issue. In addition to vaccination which is recommended by the Global initiative for chronic Obstructive Lung Disease guidelines,[@b8-copd-13-867] a nested case--control study reported that the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) was associated with a lower risk of pneumonia in patients with COPD.[@b9-copd-13-867]

Although some studies[@b9-copd-13-867]--[@b12-copd-13-867] have investigated the effect of ACEis and ARBs on the risk of pneumonia, the issue remains controversial due to differences in the study population and effects. One recent meta-analysis[@b10-copd-13-867] reported that ACEis exhibited a preventive effect equating to a relative risk ranging from 0.32 to 0.81 compared with controls, and that the overall relative risk of ACEi-treated patients versus controls was 0.61 (95% CI, 0.51--0.75; *P*\<0.001). Another population-based case--control study[@b11-copd-13-867] found that a current prescription for ACEis was associated with a reduction in the risk of pneumonia (adjusted odds ratio, 0.75; 95% CI, 0.65--0.86). In contrast, a case-crossover study using the Taiwan Longitudinal Health Insurance Database found that neither the use of nor the cumulative dose of ACEis or ARBs was associated with the risk of pneumonia among the general population in Taiwan. Moreover, it is not known which renin--angiotensin system blocker (an ACEi or ARB) is more effective in preventing pneumonia.[@b13-copd-13-867]--[@b16-copd-13-867] To date, no study has compared the effect of ACEi and ARB treatment on the risk of pneumonia in patients with COPD. Therefore, we used a national database to investigate the effect of ACEis and ARBs on the risk of pneumonia in patients with COPD. In addition, we compared the effects of ACEis and ARBs on the risk of severe exacerbations of COPD.

Patients and methods
====================

Study design and patient selection
----------------------------------

The Taiwan National Health Insurance Research Database (NHIRD) is a database constructed by the National Health Research Institutes, and includes the comprehensive medical care records of \>97% of the hospitals and clinics in Taiwan. We retrieved all claims data of ambulatory care records, outpatient visits, prescriptions, inpatient care records, registration files, and disease and vital status data from the NHIRD. The patient records and information were anonymized and de-identified prior to analysis. The study protocol was approved by the Institutional Review Board of Cardinal Tien Hospital (CTH-104-3-5-030).

This study used a subset of the NHIRD comprising information on individuals with COPD.[@b5-copd-13-867],[@b7-copd-13-867] There were 62,505 eligible COPD patients who were aged older than 40 years between 2000 and 2005. We excluded 40,026 patients who did not meet the following criteria: 1) patients without prescription of ACEi or ARB before COPD index date; 2) patients who received ACEi or ARB \<90 days after COPD index date; 3) patients with ACEi and ARB combined treatment; and 4) patients who died or were diagnosed with pneumonia or severe pneumonia prior to being indexed ([Figure 1](#f1-copd-13-867){ref-type="fig"}). Eligible patients who received prescriptions for an ACEi or ARB within 90 days after diagnosis of COPD were allocated to the ACEi and ARB cohorts. After 1:1 propensity score matching, the remaining 12,452 patients were included for further analysis ([Figure 1](#f1-copd-13-867){ref-type="fig"}).

Exposure measures and potential confounders
-------------------------------------------

We included patients who received ACEis or ARBs for \>90 days. Therefore, the index date was defined as the date of the 91st day of the prescription of ACEis or ARBs after a diagnosis of COPD. The patients were followed from the index date to 31 December 2011, the end of drug treatment, emigration, or death, whichever occurred first. The patients who changed from an ACEi to an ARB or from an ARB to an ACEi were censored.

Outcome measurements
--------------------

The primary outcomes were pneumonia and severe exacerbations. The patients with pneumonia were identified according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes as previously described.[@b5-copd-13-867],[@b17-copd-13-867] For patients with more than one episode of pneumonia, only the first episode was included. A severe exacerbation was defined as a COPD-related hospitalization or emergency department visit.[@b5-copd-13-867] The first episode of a severe exacerbation and the frequency of severe sepsis (every year) were recorded. The secondary outcome was mortality.

Demographic characteristics and comorbidities
---------------------------------------------

The demographic characteristics of the patients, including age, gender, monthly income (\<NT\$ 19,100, NT\$ 19,100--NT\$ 41,999, and \>NT\$ 42,000), hospital level at admission (medical center, regional, district, and others), and severe exacerbations of COPD in the 1 year prior to the index date (never, 1, or ≥2 times/year), were extracted. Underlying comorbid conditions were identified according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes and grouped as follows: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, rheumatologic disease, peptic ulcer disease, hemiplegia or paraplegia, renal disease, diabetes, moderate/severe liver disease, and tumor. The Charlson Comorbidity Index was used to determine the severity of comorbidities for each patient. Important medications including aspirin, clopidogrel, ticlopidine, dipyridamole, nitrates, statins, nonsteroidal anti-inflammatory drugs, anti-hyperglycemic drugs, proton-pump inhibitors, medications for hypertension (including alpha-blockers, beta-blockers, calcium channel blockers, and diuretics), and medications for COPD including long-acting beta agonists, short-acting beta agonists, long-acting muscarinic antagonists, and inhaled corticosteroids were recorded.

Statistical analysis
--------------------

Data analysis was performed using SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC, USA). The baseline characteristics were presented as descriptive statistics (means, SDs, counts, and percentages). Categorical baseline variables were compared using Pearson's chi-square test, and the independent *t*-test was used to compare continuous baseline variables. To minimize the imbalance of baseline characteristics between the ACEi and ARB groups, we performed 1:1 propensity score matching. Covariates that may have caused interference or bias in the association between exposure and outcomes of interest such as demographic characteristics, comorbidities, and severe exacerbations of COPD in the 1 year prior to the index date (never, 1, or ≥2 times/year) were included in the propensity matching.

Intention-to-treat analysis was used as the primary analysis in this study because of the more reliable real-world estimates of comparative treatment effectiveness. Both cohorts were followed until the study end according to the original treatment allocation, regardless of adherence to or subsequent withdrawal or deviation from the inclusion criteria. In the as-treated analysis, the patients were censored when they switched from an ACEi to an ARB or from an ARB to an ACEi and when they left the study because of death or emigration. We used the last time point that they were known to be alive to censor those without an event. Cumulative incidence curves were constructed using the Kaplan--Meier method, and differences between the two treatment groups were tested using the log-rank test.

The crude incidence rates of individual outcomes were calculated as the total number of events during the follow-up period divided by person-years. Cox proportional regression models were used to calculate crude hazard ratios (HRs) and adjusted hazard ratios (aHRs), which were adjusted for propensity score, of different outcomes between the ACEi and ARB groups. Annual severe exacerbation event rates (emergency department visits or admissions to hospital) were compared between the two groups using Poisson regression, with events as the dependent variable and time on a specific fixed combination treatment as an offset variable. A two-sided *P*-value \<0.05 was considered to indicate statistical significance in all analyses.

Results
=======

Characteristics of the study population
---------------------------------------

Initially, 22,479 patients with COPD who used ACEis (n=15,196) or ARBs (n=7,283) between 2000 and 2005 were included. There were significant differences between the two groups in some demographic characteristics including index year; age; gender; monthly income; hospital level; episodes of prior severe exacerbations; underlying comorbidities such as myocardial infarction, congestive heart failure, peptic ulcer disease, hemiplegia or paraplegia, and diabetes mellitus; and the use of medications including beta-blockers, calcium channel blockers, diuretics, clopidogrel, ticlopidine, dipyridamole, statins, nonsteroidal anti-inflammatory drugs, and inhalation therapy for COPD ([Table 1](#t1-copd-13-867){ref-type="table"}). Therefore, we used pairwise matching (1:1) of the ACEi and ARB groups, which resulted in two similar subgroups with 6,226 patients in each. There were no significant differences in index year, age, sex, monthly income, hospital level, inhaled medications, anti-hypertension medications, or commonly used medications including aspirin, clopidogrel, ticlopidine, dipyridamole, anti-hyperglycemic agents, and proton-pump inhibitors ([Table 1](#t1-copd-13-867){ref-type="table"}).

Effect on the risk of severe exacerbations
------------------------------------------

Following matching, the post-index all severe exacerbation rates were 0.6521 and 0.5198 per person-year in the ACEi and ARB groups, respectively (adjusted rate ratio \[RR\], 1.19; 95% CI, 1.16--1.21), as shown in [Table 2](#t2-copd-13-867){ref-type="table"}. The patients treated with ACEis had significantly higher rates of COPD exacerbations requiring hospitalization (adjusted RR, 1.24; 95% CI, 1.21--1.28) or emergency department visit (adjusted RR, 1.16; 95% CI, 1.13--1.18), as shown in [Table 2](#t2-copd-13-867){ref-type="table"}. The results before matching were the same as after matching.

Effect on the risk of pneumonia and death
-----------------------------------------

During the follow-up period, the incidence of pneumonia was 7.39 per 100 person-years for the patients receiving ACEis and 5.66 per 100 person-years for those receiving ARBs. Moreover, the ACEi group had a higher risk of pneumonia (aHR, 1.20; 95% CI, 1.14--1.26) than the ARB group. Furthermore, the incidence of pneumonia requiring mechanical ventilation was 2.90 per 100 person-years in the ACEi group and 1.97 per 100 person-years in the ARB group, and the ACEi group had a higher risk of pneumonia requiring mechanical ventilation (aHR, 1.34; 95% CI, 1.24--1.45) than the ARB group. Finally, the mortality rate was 5.82 per 100 person-years in the ACEi group and 3.90 per 100 person-years in the ARB group. Overall, the patients receiving ACEis had a higher risk of death (aHR, 1.29; 95% CI, 1.22--1.37) than those receiving ARBs. When we treated death as a competing risk, the ACEi group had a higher risk of pneumonia and pneumonia requiring mechanical ventilation than the ARB group. Similar trends were noted after using propensity score matching, and the ACEi group had a higher risk of pneumonia and pneumonia requiring mechanical ventilation than the ARB group, even when treating death as a competing risk ([Table 3](#t3-copd-13-867){ref-type="table"}).

Sensitivity analysis
--------------------

[Table 4](#t4-copd-13-867){ref-type="table"} shows the sensitivity analysis of the risk of pneumonia and death among the patients with COPD receiving ACEis compared to the matched patients receiving ARBs. When we treated death as a competing risk in the intention-to-treat analysis, the patients receiving ACEis had a higher risk of pneumonia and pneumonia requiring mechanical ventilation compared to the matched patients receiving ARBs (aHR, 1.19; 95% CI, 1.13--1.26 for pneumonia; aHR, 1.19; 95% CI, 1.13--1.25 for pneumonia requiring mechanical ventilation). In the as-treated analysis, the patients receiving ACEis had a higher risk of pneumonia and pneumonia requiring mechanical ventilation compared to the matched patients receiving ARBs. When death was treated as a competing risk in the as-treated analysis, the patients receiving ACEis had a higher risk of pneumonia than those receiving ARBs (aHR, 1.08; 95% CI, 1.01--1.15). The results of analysis conducted before propensity score matching were consistent with those after propensity score matching.

Discussion
==========

In this large national study, we compared the effect of the prior use of ACEis and ARBs on the risk of pneumonia and severe exacerbations in patients with COPD. After adjusting for possible confounding factors and using different methods of analysis, the risks of pneumonia and severe exacerbations were significantly higher in the patients who received ACEis than in those who received ARBs. In addition, the patients with COPD who used ACEis had a significantly higher mortality rate than those who used ARBs. Taken together, these findings suggest that ARBs are associated with fewer COPD complications, including severe exacerbations, pneumonia, and mortality, than ACEis, and this may further suggest that ARBs are more appropriate for patients with COPD, in terms of the risk of severe exacerbations and pneumonia, than ACEis.

A previous study investigating the effects of ACEis and ARBs on the risk of pneumonia did not find any obvious differences between ACEis and ARBs in the general population.[@b12-copd-13-867] In contrast, another study enrolling patients with hypertension found that ARB users, but not ACEi users had lower rates of hospitalization for sepsis, compared with untreated hypertensive patients.[@b13-copd-13-867] In this study, we found significant differences between ACEi and ARB treatments in terms of COPD exacerbations and the risk of pneumonia. The difference between this study and previous reports[@b12-copd-13-867],[@b13-copd-13-867] may be due to different study populations, and further studies are warranted to investigate differences in the effects between ACEis and ARBs in specific populations. Regarding the effect on mortality between the ACEi and ARB groups, our findings are consistent with a time-matched nested case--control study in which ARB users seemed to have a lower mortality rate than ACEi users.[@b6-copd-13-867]

The significant difference in complications of COPD between users of ARBs and ACEis may be explained by their different mechanisms of action on the renin--angiotensin system in pulmonary diseases.[@b10-copd-13-867],[@b11-copd-13-867],[@b18-copd-13-867] In an animal model, valsartan was shown to be protective against bleomycin-induced pulmonary injuries via the suppression of total and active transforming growth factor-beta 1.[@b11-copd-13-867] Another investigation[@b18-copd-13-867] demonstrated that candesartan can reduce bleomycin-induced lung fibrosis. In addition, ARBs have been reported to be able to use the ACE2/AT2R/Mas axis to ameliorate inflammation.[@b19-copd-13-867],[@b20-copd-13-867] These additional effects of ARBs may result in the differences with ACEis with regards to the risk and outcomes of severe exacerbations and pneumonia in patients with COPD.

The strength of this study is that we enrolled a large cohort of patients with COPD and various cardiovascular risk profiles with a long follow-up period, which represents the general condition in real-word practice. Based on the data from the NHIRD, we were able to analyze many known confounding factors including comorbidities, drug usage, and the frequency of severe exacerbations, which allowed us to minimize the effects of confounders.

This study also has several limitations. First, as with all studies based on claims databases, some confounders such as pulmonary function and clinical symptoms and signs were not available for analysis. Therefore, we could not evaluate the severity of COPD. However, we used episodes of severe exacerbations to partly represent the severity of COPD. Second, only data on all-cause mortality are contained in the NHIRD, so we could not analyze specific causes of death. Therefore, we could not analyze whether the difference in mortality rates between the ACEi and ARB groups was due to cardiovascular event-related death or another etiology.

Conclusion
==========

ARB treatment was associated with lower rates of severe exacerbations, pneumonia, and mortality than ACEi treatment in patients with COPD.
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###### 

Demographic characteristics of the study subjects

  Variables                                    Before matching   After matching                                                                            
  -------------------------------------------- ----------------- ---------------- ---------- ------------- ------------ -------- -------- ------- -------- --------
  Number of patients                           15,196            7,283                       6,226         6,226                                           
  Index year                                                                                                                                               
   2000                                        3,763             24.76%           768        10.55%        \<0.0001     736      11.82%   768     12.34%   0.9693
   2001                                        2,985             19.64%           884        12.14%                     883      14.18%   880     14.13%   
   2002                                        2,552             16.79%           1,109      15.23%                     1,068    17.15%   1,047   16.82%   
   2003                                        2,017             13.27%           1,336      18.34%                     1,132    18.18%   1,130   18.15%   
   2004                                        2,002             13.17%           1,695      23.27%                     1,264    20.30%   1,264   20.30%   
   2005                                        1,877             12.35%           1,491      20.47%                     1,143    18.36%   1,137   18.26%   
  Age (years, SD)                              68.15±9.77        66.75±9.95       \<0.0001   67.43±10.01   67.24±9.82   0.2919                             
  Male gender                                  11,071            72.85%           4,983      68.42%        \<0.0001     4,405    70.75%   4,359   70.01%   0.3666
  Monthly income NT\$, n (%)                                                                                                                               
   \<19,100                                    6,597             43.41%           2,973      40.82%        \<0.0001     2,658    42.69%   2,625   42.16%   0.8336
   19,100--41,999                              7,050             46.39%           3,262      44.79%                     2,784    44.72%   2,807   45.09%   
   ≥42,000                                     1,549             10.19%           1,048      14.39%                     784      12.59%   794     12.75%   
  Hospital level, n (%)                                                                                                                                    
   Level 1                                     3,360             22.11%           3,095      42.50%        \<0.0001     2,374    38.13%   2,366   38.00%   0.593
   Level 2                                     3,625             23.85%           2,254      30.95%                     1,959    31.46%   1,994   32.03%   
   Level 3                                     3,088             20.32%           1,335      18.33%                     1,319    21.19%   1,267   20.35%   
   Level 4                                     5,123             33.71%           599        8.22%                      574      9.22%    599     9.62%    
  Severe AE (count 1 year before index date)                                                                                                               
   0                                           10,277            67.63%           5,354      73.51%        \<0.0001     4,466    71.73%   4,446   71.41%   0.9181
   1                                           2,190             14.41%           918        12.60%                     827      13.28%   833     13.38%   
   2+                                          2,729             17.96%           1,011      13.88%                     933      14.99%   947     15.21%   
  Baseline comorbidities                                                                                                                                   
   Charlson score                              1.82±1.06         1.80±1.05        0.4771     1.84±1.07     1.82±1.05    0.3405                             
   Myocardial infarction                       391               2.57%            131        1.80%         0.0003       142      2.28%    128     2.06%    0.389
   Congestive heart failure                    2,164             14.24%           849        11.66%        \<0.0001     824      13.23%   796     12.79%   0.4557
   Peripheral vascular disease                 156               1.03%            71         0.97%         0.7167       70       1.12%    59      0.95%    0.3303
   Cerebrovascular disease                     1,675             11.02%           786        10.79%        0.6047       687      11.03%   679     10.91%   0.8186
   Dementia                                    181               1.19%            87         1.19%         0.9822       81       1.30%    75      1.20%    0.6288
   Rheumatologic disease                       141               0.93%            74         1.02%         0.5249       60       0.96%    66      1.06%    0.5911
   Peptic ulcer disease                        2,830             18.62%           1,187      16.30%        \<0.0001     1,087    17.46%   1,068   17.15%   0.6526
   Hemiplegia or paraplegia                    23                0.15%            15         0.21%         0.3510       9        0.14%    10      0.16%    0.8184
   Renal disease                               458               3.01%            275        3.78%         0.0026       216      3.47%    228     3.66%    0.562
   Diabetes                                    1,650             10.86%           933        12.81%        \<0.0001     799      12.83%   787     12.64%   0.747
   Moderate or severe liver disease            682               4.49%            337        4.63%         0.6387       281      4.51%    299     4.80%    0.444
   Tumor                                       410               2.70%            223        3.06%         0.1228       202      3.24%    191     3.07%    0.5729
  Medication for hypertension                                                                                                                              
   Alpha-blocker                               2,056             13.53%           936        12.85%        0.1613       846      13.59%   831     13.35%   0.6938
   Beta-blocker                                6,354             41.81%           3,156      43.33%        0.0309       2,671    42.90%   2,671   42.90%   1
   Calcium channel blocker                     9,748             64.15%           5,128      70.41%        \<0.0001     4,299    69.05%   4,306   69.16%   0.892
   Diuretic                                    7,825             51.49%           3,474      47.70%        \<0.0001     3,095    49.71%   3,042   48.86%   0.3421
  Other medication                                                                                                                                         
   Aspirin                                     2,220             14.61%           1,115      15.31%        0.1667       953      15.31%   927     14.89%   0.5152
   Clopidogrel                                 356               2.34%            340        4.67%         \<0.0001     265      4.26%    267     4.29%    0.9294
   Ticlopidine                                 591               3.89%            237        3.25%         0.0180       219      3.52%    220     3.53%    0.9612
   Dipyridamole                                4,415             29.05%           1,563      21.46%        \<0.0001     1,444    23.19%   1,432   23.00%   0.7986
   Nitrate                                     46                0.30%            23         0.32%         0.8681       21       0.34%    22      0.35%    0.8786
   Statin                                      1,167             7.68%            1,031      14.16%        \<0.0001     725      11.64%   733     11.77%   0.8236
   NSAID                                       12,905            84.92%           5,929      81.41%        \<0.0001     5,073    81.48%   5,111   82.09%   0.3776
   Anti-hyperglycemic drugs                    2,560             16.85%           1,275      17.51%        0.2183       1,127    18.10%   1,102   17.70%   0.5589
   Proton-pump inhibitor                       1,211             7.97%            611        8.39%         0.2800       547      8.79%    533     8.56%    0.6558
  COPD drug                                                                                                                                                
   Long-acting beta-agonist                    670               4.41%            396        5.44%         0.0007       317      5.09%    327     5.25%    0.6857
   Short-acting beta-agonist                   3,171             20.87%           1,432      19.66%        0.0361       1,253    20.13%   1,236   19.85%   0.7032
   Long-acting muscarinic antagonist           85                0.56%            80         1.10%         \<0.0001     59       0.95%    60      0.96%    0.9266
   Inhaled corticosteroid                      2,323             15.29%           1,479      20.31%        \<0.0001     1,147    18.42%   1,196   19.21%   0.2612

**Abbreviations:** AE, acute exacerbation; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory drug.

###### 

Annual incidence and RR of severe exacerbation of COPD

  Variables                                            ACEi cohort   ARB cohort   Crude RR (95% CI)   Adjusted RR[a](#tfn2-copd-13-867){ref-type="table-fn"} (95% CI)
  ---------------------------------------------------- ------------- ------------ ------------------- -----------------------------------------------------------------
  Before propensity score matching                                                                    
   Severe exacerbation                                 0.6873        0.5109       1.32 (1.30--1.34)   1.19 (1.17--1.21)
   Hospitalization for COPD exacerbation               0.3573        0.23579      1.49 (1.46--1.52)   1.27 (1.25--1.30)
   Emergency department visits for COPD exacerbation   0.4639        0.3765       1.21 (1.19--1.23)   1.14 (1.12--1.16)
  After propensity score matching                                                                     
   Severe exacerbation                                 0.6521        0.5198       1.19 (1.17--1.21)   1.19 (1.16--1.21)
   Hospitalization for COPD exacerbation               0.3213        0.2438       1.25 (1.21--1.28)   1.24 (1.21--1.28)
   Emergency department visits for COPD exacerbation   0.4620        0.3778       1.16 (1.13--1.18)   1.16 (1.13--1.18)

**Note:**

Adjusted for propensity score.

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; RR, rate ratio.

###### 

Annual IR and risk of pneumonia among COPD patients

  Variables                          ACEi cohort   ARB cohort   Crude   Adjusted[b](#tfn5-copd-13-867){ref-type="table-fn"}   Competing risk                                                  
  ---------------------------------- ------------- ------------ ------- ----------------------------------------------------- ---------------- ------ ------------------- ------------------- -------------------
  Before propensity score matching                                                                                                                                                            
   Mortality                         6,277         107,841.55   5.82    2,057                                                 52,759.75        3.90   1.50 (1.42--1.57)   1.29 (1.22--1.37)   --
   Pneumonia                         6,516         88,135.31    7.39    2,564                                                 45,316.88        5.66   1.30 (1.24--1.36)   1.20 (1.14--1.26)   1.15 (1.09--1.20)
   Pneumonia requiring MV            3,005         103,492.68   2.90    1,010                                                 51,298.54        1.97   1.47 (1.37--1.58)   1.34 (1.24--1.45)   1.15 (1.09--1.20)
  After propensity score matching                                                                                                                                                             
   Mortality                         2,326         42,503.29    5.47    1,864                                                 45,472.26        4.10   1.33 (1.25--1.42)   1.33 (1.26--1.42)   --
   Pneumonia                         2,536         35,204.12    7.20    2,281                                                 38,750.59        5.89   1.22 (1.15--1.29)   1.22 (1.15--1.29)   1.19 (1.13--1.26)
   Pneumonia requiring MV            1,122         40,864.53    2.75    899                                                   44,158.63        2.04   1.35 (1.23--1.47)   1.35 (1.24--1.47)   1.19 (1.13--1.25)

**Notes:**

Per 100 person-years.

Adjusted for propensity score.

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HR, hazard ratio; IR, incidence rate; MV, mechanical ventilation; subHR, subdistribution hazard ratio.

###### 

Sensitivity analysis

  Variables                              Before matching     After matching                          
  -------------------------------------- ------------------- ------------------- ------------------- -------------------
  Primary analysis                                                                                   
   Mortality                             1.5 (1.42--1.57)    1.29 (1.22--1.37)   1.33 (1.25--1.42)   1.33 (1.26--1.42)
   Pneumonia                             1.3 (1.24--1.36)    1.2 (1.14--1.26)    1.22 (1.15--1.29)   1.22 (1.15--1.29)
   Pneumonia requiring MV                1.47 (1.37--1.58)   1.34 (1.24--1.45)   1.35 (1.23--1.47)   1.35 (1.24--1.47)
  ITT analysis + competing risk                                                                      
   Mortality                                                                                         
   Pneumonia                             1.04 (1--1.09)      1.15 (1.09--1.2)    1.19 (1.13--1.26)   1.19 (1.13--1.26)
   Pneumonia requiring MV                0.96 (0.92--1)      1.15 (1.09--1.2)    1.19 (1.12--1.25)   1.19 (1.13--1.25)
  As-treated analysis                                                                                
   Mortality                             1.5 (1.4--1.61)     1.28 (1.19--1.38)   1.29 (1.19--1.4)    1.3 (1.2--1.41)
   Pneumonia                             1.28 (1.21--1.36)   1.17 (1.1--1.26)    1.16 (1.08--1.25)   1.17 (1.09--1.26)
   Pneumonia requiring MV                1.38 (1.25--1.52)   1.25 (1.13--1.39)   1.21 (1.07--1.36)   1.21 (1.08--1.37)
  As-treated analysis + competing risk                                                               
   Mortality                                                                                         
   Pneumonia                             1.07 (1.01--1.13)   1.06 (1--1.12)      1.07 (1--1.15)      1.08 (1.01--1.15)
   Pneumonia requiring MV                1.01 (0.96--1.07)   1.03 (0.97--1.1)    1.04 (0.98--1.12)   1.04 (0.97--1.12)

**Note:**

Adjusted for propensity score.

**Abbreviations:** HR, hazard ratio; ITT, intention-to-treat; MV, mechanical ventilation.
